EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients

Michael B Lilly, Chunli Wu, Yu Ke, Wen-Pin Chen, Adam C Soloff, Kent Armeson, Noriko N Yokoyama, Xiaotian Li, Liankun Song, Ying Yuan, Christine E McLaren, Xiaolin Zi iD

Clinical and Translational Medicine · 2024

DOI: 10.1002/ctm2.1627 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Medicine, 2024. Verfasst von Michael B Lilly und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Our preclinical studies showed that lycopene enhanced the anti‐prostate cancer efficacy of docetaxel in animal models. A phase I trial (NCT0149519) was conducted to identify an optimum dose of synthetic lycopene in combination with docetaxel (and androgen blockade [androgen deprivation therapy, ADT]), and to evaluate its effect on the safety and pharmacokinetics of docetaxel in men with metastatic prostate cancer.

Methods

Subjects were treated with 21‐day cycles of 75 mg/m 2 docetaxel (and ADT), plus lycopene at 30, 90 or 150 mg/day. A Bayesian model averaging continual reassessment method was used to guide dose escalation. Pharmacokinetics of docetaxel and multiple correlative studies were carried out.

Results

Twenty‐four participants were enrolled, 18 in a dose escalation cohort to define the maximum tolerated dose (MTD), and six in a pharmacokinetic cohort. Docetaxel/ADT plus 150 mg/day synthetic lycopene resulted in dose‐limiting toxicity (pulmonary embolus) in one out of 12 participants with an estimated probability of .106 and thus was chosen as the MTD. Lycopene increased the AUC inf and C max of plasma docetaxel by 9.5% and 15.1%, respectively. Correlative studies showed dose‐related changes in circulating endothelial cells and vascular endothelial growth factor A, and reduction in insulin‐like growth factor 1R phosphorylation, associated with lycopene therapy.

Conclusions

The combination of docetaxel/ADT and synthetic lycopene has low toxicity and favourable pharmacokinetics. The effects of lycopene on biomarkers provide additional support for the toxicity‐dependent MTD definition. Highlights The maximum tolerated dose was identified as 150 mg/day of lycopene in combination with docetaxel/ADT for the treatment of metastatic prostate cancer patients. Small increases in plasma exposure to docetaxel were observed with lycopene co‐administration. Mechanistically significant effects were seen on angiogenesis and insulin‐like growth factor 1 signalling by lycopene co‐administration with docetaxel/ADT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMaleHumansDocetaxelLycopeneVascular Endothelial Growth Factor AAndrogen AntagonistsAndrogensBayes TheoremEndothelial Cells

Stichwörter der Autor:innen

docetaxellycopenephase I trialprostate cancer

Substanzen

DocetaxelLycopeneVascular Endothelial Growth Factor AAndrogen AntagonistsAndrogens

Autor:innen und Institutionen

  • Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Department of Urology, University of California, Irvine, California, USA.
  • Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA.
  • Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
  • Department of Biostatistics, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Xiaolin Zi

Förderung

  • BLRD VA
  • NCI NIH HHS
  • NCATS NIH HHS
  • National Cancer Institute
  • Chao Family Comprehensive Cancer Center

Zitieren

APA

Lilly, M. B., Wu, C., Ke, Y., Chen, W. P., Soloff, A. C., Armeson, K., Yokoyama, N. N., Li, X., Song, L., Yuan, Y., McLaren, C. E., & Zi, X. (2024). A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.1627

Vancouver

Lilly MB, Wu C, Ke Y, Chen WP, Soloff AC, Armeson K, et al. A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients. Clinical and Translational Medicine. 2024. doi:10.1002/ctm2.1627

BibTeX
@article{Lilly2024,
  author = {Lilly, Michael B and Wu, Chunli and Ke, Yu and Chen, Wen-Pin and Soloff, Adam C and Armeson, Kent and Yokoyama, Noriko N and Li, Xiaotian and Song, Liankun and Yuan, Ying and McLaren, Christine E and Zi, Xiaolin},
  title = {A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients},
  journal = {Clinical and Translational Medicine},
  year = {2024},
  doi = {10.1002/ctm2.1627}
}
Kostenlos starten →